Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on developing curative therapies for heart disease, announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.
CEO Faraz Ali will engage in a fireside chat on September 9, 2025, at 4:50 pm ET. Investors can access the live webcast through Tenaya's website's Investor section, with a replay available for approximately 30 days after the event.
Tenaya Therapeutics (NASDAQ: TNYA), una biotech in fase clinica dedicata allo sviluppo di terapie curative per le malattie cardiache, ha annunciato la sua partecipazione al Morgan Stanley 23rd Annual Global Healthcare Conference.
Il CEO Faraz Ali parteciper脿 a una fireside chat il 9 settembre 2025 alle 16:50 ET. Gli investitori potranno seguire il webcast in diretta nella sezione Investor del sito web di Tenaya; la replica sar脿 disponibile per circa 30 giorni dopo l'evento.
Tenaya Therapeutics (NASDAQ: TNYA), una biotecnol贸gica en fase cl铆nica centrada en desarrollar terapias curativas para enfermedades del coraz贸n, anunci贸 su participaci贸n en la Morgan Stanley 23rd Annual Global Healthcare Conference.
El CEO Faraz Ali participar谩 en una charla el 9 de septiembre de 2025 a las 4:50 p.m. ET. Los inversores podr谩n acceder a la retransmisi贸n en directo a trav茅s de la secci贸n Investor del sitio web de Tenaya; la grabaci贸n estar谩 disponible durante aproximadamente 30 d铆as tras el evento.
Tenaya Therapeutics (NASDAQ: TNYA)电� 鞁灔歆堩櫂鞐� 雽�頃� 旃橃湢鞝� 旃橂氩� 臧滊皽鞐� 欤茧牓頃樀鐢 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤鞙茧, Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
CEO Faraz Ali电� 2025雲� 9鞗� 9鞚� 鞓ろ泟 4鞁� 50攵�(霃欕秬鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳劃頃╇媹雼�. 韴瀽鞛愲摛鞚� Tenaya 鞗轨偓鞚错姼鞚� Investor 靹轨厴鞚� 韱淀暣 靸濎瓿勲ゼ 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓臧� 雭濍倻 頉� 鞎� 30鞚缄皠 鞛癌靻§潉 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Tenaya Therapeutics (NASDAQ: TNYA), une biotech en phase clinique d茅di茅e au d茅veloppement de th茅rapies curatives pour les maladies cardiaques, a annonc茅 sa participation 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference.
Le CEO Faraz Ali prendra part 脿 une discussion fireside le 9 septembre 2025 脿 16h50 (heure de l'Est). Les investisseurs pourront suivre la diffusion en direct via la section Investor du site de Tenaya ; un replay sera disponible pendant environ 30 jours apr猫s l'茅v茅nement.
Tenaya Therapeutics (NASDAQ: TNYA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das kurative Therapien f眉r Herzkrankheiten entwickelt, gab seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference bekannt.
CEO Faraz Ali wird an einem Fireside-Chat am 9. September 2025 um 16:50 Uhr ET teilnehmen. Investoren k枚nnen das Live-Webcast 眉ber den Investor-Bereich der Tenaya-Website verfolgen; eine Aufzeichnung steht rund 30 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya鈥檚 Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET.
The live webcast of the fireside chat may be accessed from the Investors section of . An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About聽Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya鈥檚 pipeline includes clinical-stage candidates TN-201, a gene therapy for聽MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for聽PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit聽.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
Investors
Anne-Marie Fields
Precision AQ
FAQ
When is Tenaya Therapeutics (TNYA) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Tenaya Therapeutics' Morgan Stanley conference presentation?
Who will represent Tenaya Therapeutics at the Morgan Stanley Healthcare Conference?
What is Tenaya Therapeutics' (TNYA) main business focus?
